Omega Drugs Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 1.73 M
- Company Age 39 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 5.29 M
About Omega Drugs
Omega Drugs Pvt Ltd (ODPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 August 1985 and has a history of 39 years and six months. Its registered office is in Mumbai, Maharashtra.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.73 M.
The company has closed loans amounting to ₹5.29 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Kiran Shah and Vijay Nagardas serve as directors at the Company.
Company Details
- Location Mumbai, Maharashtra
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24230MH1985PTC037098
-
Company No.
037098
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
09 Aug 1985
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Omega Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kiran Shah
|
Director | 09-Aug-1985 | Current |
|
Vijay Nagardas
|
Director | 09-Aug-1985 | Current |
Financial Performance of Omega Drugs.
Omega Drugs Pvt Ltd, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Omega Drugs?
In 2017, Omega Drugs had a promoter holding of 25.56% and a public holding of 74.44%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹5.29 M
Charges Breakdown by Lending Institutions
- Gujarat State Financial Corporation : 0.37 Cr
- Bank Of Baroda : 0.09 Cr
- Bank Baroda : 0.07 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Oct 1990 | Bank Baroda | ₹0.71 M | Satisfied |
| 26 Oct 1990 | Bank Of Baroda | ₹0.87 M | Satisfied |
| 11 Oct 1988 | Gujarat State Financial Corporation | ₹3.71 M | Satisfied |
How Many Employees Work at Omega Drugs?
Unlock and access historical data on people associated with Omega Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Omega Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Omega Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
